- Home
- NBXG vs CDNA Comparison
NBXG vs CDNA Comparison
Compare NBXG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | CDNA |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NBXG | CDNA |
|---|---|---|
| Price | $14.55 | $19.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 243.7K | ★ 722.8K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | N/A | $11.75 |
| P/E Ratio | ★ N/A | $15.75 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $9.31 | $10.96 |
| 52 Week High | $12.23 | $25.95 |
Technical Indicators
Market Signals| Indicator | NBXG | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 54.20 |
| Support Level | $14.37 | $19.01 |
| Resistance Level | $14.67 | $20.61 |
| Average True Range (ATR) | 0.24 | 0.71 |
| MACD | 0.04 | -0.22 |
| Stochastic Oscillator | 91.95 | 18.43 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.